Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTC Therapeutics, Inc.

http://www.ptcbio.com/

Latest From PTC Therapeutics, Inc.

Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Coronavirus COVID-19 Research and Development Strategies

Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential

The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.

Cancer Blood & Coagulation Disorders

Deal Watch: Celgene CVR From BMS Buyout Falls Through

Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.

Deals Business Strategies

Gilead Turns Back To Virology With $1.4bn MYR Acquisition

MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Agilis Biotherapeutics, Inc.
    • Censa Pharmaceuticals Inc.
UsernamePublicRestriction

Register